What We’re Reading: Efficacy of AstraZeneca Vaccine; FDA Grants EUA for Antibody Cocktail; Assessing Ventilator Usage
AstraZeneca announced that its vaccine against coronavirus disease 2019 (COVID-19) could be up to 90% effective; FDA grants emergency use authorization (EUA) for antibody cocktail used against COVID-19; spotlighting shortage of specialists to operate ventilators.
AstraZeneca-Oxford Vaccine Reported to Be 90% Effective
Today, AstraZeneca announced that its vaccine against coronavirus disease 2019 (COVID-19) could be approximately 90% effective when administered as a half dose followed by a full dose at least a month later. As reported by
FDA Grants EUA For Second COVID-19 Antibody Treatment
The antibody cocktail (casirivimab and imdeveimab) manufactured by the biotech company Regeneron, which was administered to President Donald Trump while he was battling COVID-19, has been granted an emergency use authorization (EUA) by the FDA.
Assessing Ventilator Usage and Workforce
While cases of COVID-19 continue to surge nationwide, an article by
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Rural-Urban Disparities in Colorectal Cancer Screening Persist
September 21st 2025
- AML Survival After 3 Years in Remission Comparable With General Population
September 20th 2025
- AHA Launches New Initiative to Help Patients With Heart Failure
September 20th 2025
- CSU More Burdensome in Female Patients, Especially in Midlife
September 20th 2025
- Pirtobrutinib Shows Clinically Meaningful PFS Improvement in Frontline CLL
September 19th 2025